Cancer Risk Reduction Through Combined Treatment for Tobacco and Alcohol Use
RATIONALE: A counseling program that motivates patients to stop smoking and drinking may reduce the risk of oral cancer. It is not yet known whether motivational stop smoking counseling or motivational stop-smoking and stop drinking counseling is more effective in helping patients stop smoking and drinking.
PURPOSE: This randomized clinical trial is studying how well treatment to stop smoking and drinking works in preventing oral cancer in smokers in Puerto Rico.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
OBJECTIVES:
- To evaluate the effects of a motivational and problem-solving smoking cessation (MAPS) and a motivational and problem solving approach on at-risk alcohol use and smoking cessation (MAPS+) among Puerto Rican at-risk drinkers/smokers who call the Puerto Rico Quitline (PRQ).
- To assess effects of MAPS and MAPS+ on treatment mechanisms and the role of those mechanisms in mediating these effects on at-risk drinking and smoking cessation.
- To evaluate the cost-effectiveness of MAPS and MAPS+ in the reduction of at-risk drinking and smoking cessation.
OUTLINE: Minimization randomization is applied using the following variables: age, gender, cigarettes/day, number of drinks/day, and depression (score on the Center of Epidemiologic Studies Depression Scale). Patients are randomized to 1 of 2 intervention arms.
- Arm I (MAPS): Patients receive culturally sensitive self-help materials tailored for alcohol and tobacco users and 7 telephone counseling calls. The MAPS approach includes motivational interviewing and cognitive behavioral/problem-solving that focus on smoking cessation.
- Arm II (MAPS+): Patients receive culturally sensitive self-help materials tailored for alcohol and tobacco users and 7 telephone counseling calls. The MAPS+ approach includes motivational interviewing and cognitive behavioral/problems solving that focus on smoking cessation and the reduction of at-risk alcohol use.
In both arms, patients receive counseling calls over 15-30 minutes the week before quit date (QD), on QD, 3-5 days after QD, 7-10 days after QD, 15-30 days after QD, 45-60 days after QD, and on day 90 after QD. Patients complete questionnaires for alcohol- and smoking-related measures, self efficacy, stress/negative affects/depression, social support, and physical activity at baseline and weeks 12, 26 and 52 after QD.
Tipo di studio
Iscrizione (Anticipato)
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
DISEASE CHARACTERISTICS:
- Current daily smoker
- Called the Puerto Rico Quitline
- Motivated to quit smoking in the next 30 days
Exhibits at least one of the following criteria for at-risk drinking:
- An average of ≥ 2 alcoholic beverages/day for men or ≥ 1 drink/day for women in the past 30 days
- Two or more occasions of consuming ≥ 5 alcoholic beverages/day for men or ≥ 4 drinks/day for women in the past 30 days
- Driving after consuming ≥ 3 drinks in the past 30 days
- Score of ≤ 15 on the Alcohol Use Disorders Identification Test
PATIENT CHARACTERISTICS:
- Not pregnant
- Residing in Puerto Rico
- Not currently incarcerated or in jail
- No other household member enrolled in this study
- Viable telephone number and home address
- Willing to provide the names, addresses, and phone numbers of up to 3 collaterals
PRIOR CONCURRENT THERAPY:
- Not specified
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
MAPS+
MAPS+ (Motivation and Problem-Solving Plus): Counseling using specific treatment approach that focuses on combined smoking cessation and the reduction of at-risk alcohol use. |
Altri nomi:
Standard quit-smoking counseling to help decrease their risk of cancer.
Counseling focusing on decreasing risk of getting cancer by decreasing smoking and alcohol use.
|
|
MAPS
MAPS (Motivation and Problem-Solving): Counseling treatment approach with a focus on smoking cessation. |
Altri nomi:
Standard quit-smoking counseling to help decrease their risk of cancer.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Smettere di fumare
Lasso di tempo: 52 settimane
|
52 settimane
|
|
Participant At-risk drinking status
Lasso di tempo: 52 weeks
|
52 weeks
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Cattedra di studio: David Wetter, PhD, MS, BA, M.D. Anderson Cancer Center
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CDR0000626365 (Altro identificatore: NCI Clinical Trials)
- U54CA096300 (Sovvenzione/contratto NIH degli Stati Uniti)
- U54CA096297 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2012-02110 (Identificatore di registro: NCI CTRP)
- MDA-2005-0791
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su somministrazione del questionario
-
Virginia Commonwealth UniversityRigel PharmaceuticalsReclutamentoLeucemia mieloide acutaStati Uniti
-
Cairn DiagnosticsCompletato
-
Nova Scotia Health AuthorityNon ancora reclutamento
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); GlaxoSmithKline; Stanford University e altri collaboratoriReclutamentoMalaria | Plasmodium Vivax MalariaPerù
-
Brown UniversityCompletato
-
Pyae Linn AungUniversity of South Florida; Mahidol UniversityAttivo, non reclutanteMalaria | Plasmodium Vivax | Myanmar | Amministrazione farmaceutica di massa | PrimachinaBirmania
-
Universitas Negeri SemarangMinistry of Research, Technology and Higher Education, Republic of IndonesiaSconosciutoLo stress ossidativo | Sforzo; EccessoIndonesia
-
University Hospital PadovaCompletatoSindrome da distress respiratorio, neonatoItalia
-
Weill Medical College of Cornell UniversityNew York Presbyterian HospitalReclutamento
-
Washington University School of MedicineCompletatoFilariosi linfatica | Oncocercosi | Infezioni da elminti trasmessi dal suolo (STH).Liberia